Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflornithine and sulindac in familial adenomatous polyposis
NCT01245816Phase 3Withdrawn
- Start
- Mar 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of eflornithine in familial adenomatous polyposis (FAP). Planned start Mar 2011; status: withdrawn.
02
Drugs
eflornithine
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT01245816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245816.